Novo Nordisk cut its 2025 guidance and outgoing CEO blames the compounding market for it.
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
July 29, 2025
You may also like
Indices by TradingView
Amazon vs. Costco: Which Stock Is a Better Buy?
February 28, 2026
Cross Staff Loads Up on 289,000 Shares of AKRE
February 28, 2026
The billion-dollar infrastructure deals powering the AI boom
February 28, 2026
AI Boom May Be Creating Hidden Risks In Housing Market
February 28, 2026
Categories
Indices by TradingView





